Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer.

Trial Profile

Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Feb 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Pemetrexed (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Jan 2014 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov record
    • 12 Dec 2012 Planned end date changed from 1 Oct 2012 to 1 Jul 2015 as reported by ClinicalTrials.gov.
    • 12 Dec 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top